DWP DN11
Alternative Names: DWP-DN11Latest Information Update: 09 Mar 2023
At a glance
- Originator Daewoo Pharm
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Dry eyes
Most Recent Events
- 09 Mar 2023 Phase-III clinical trials in Dry eyes in South Korea (unspecified route) before March 2023 (Daewoo Pharm pipeline, March 2023)